Cargando…

Anabolic therapy for osteoporosis: update on efficacy and safety

Anabolic agents for the treatment of osteoporosis increase bone density, improve bone strength, and reduce fracture risk. They are distinguished from antiresorptive drugs by their property of increasing osteoblastic bone formation. Teriparatide and abaloparatide are parathyroid hormone receptor agon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bandeira, Leonardo, Lewiecki, E. Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Endocrinologia e Metabologia 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118815/ https://www.ncbi.nlm.nih.gov/pubmed/36382760 http://dx.doi.org/10.20945/2359-3997000000566

Ejemplares similares

A review of anabolic therapies for osteoporosis
por: Lane, Nancy E, et al.
Publicado: (2003)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Anabolic Therapies in Osteoporosis and Bone Regeneration
por: Russow, Gabriele, et al.
Publicado: (2018)

Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy
por: Taylor, Adam D, et al.
Publicado: (2019)

Management of osteoporosis
por: Lewiecki, E Michael
Publicado: (2004)

Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
por: Leder, Benjamin Z
Publicado: (2018)

Update on the safety and efficacy of teriparatide in the treatment of osteoporosis
por: Minisola, Salvatore, et al.
Publicado: (2019)

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2009)

Anabolic treatments for osteoporosis in postmenopausal women
por: Hassan, Neelam, et al.
Publicado: (2021)

Operationalizing Treat-to-Target for Osteoporosis
por: Lewiecki, E. Michael
Publicado: (2021)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
por: Lewiecki, E Michael
Publicado: (2010)

Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update
por: Messalli, Enrico M, et al.
Publicado: (2010)

Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis
por: Shah, Arti D, et al.
Publicado: (2015)

Antiresorptive Versus Anabolic Therapy in Managing Osteoporosis in People with Type 1 and Type 2 Diabetes
por: Vilaca, Tatiane, et al.
Publicado: (2023)

Advancement in the Treatment of Osteoporosis and the Effects on Bone Healing
por: Kushchayeva, Yevgeniya, et al.
Publicado: (2022)

New and Emerging Therapies for Osteoporosis
por: Lewiecki, E. Michael, et al.
Publicado: (2010)

Male osteoporosis
por: Bandeira, Leonardo, et al.
Publicado: (2022)

Romosozumab, clinical trials, and real-world care of patients with osteoporosis
por: Lewiecki, E. Michael
Publicado: (2020)

Bone-targeted pH-responsive cerium nanoparticles for anabolic therapy in osteoporosis
por: Dou, Ce, et al.
Publicado: (2021)

Corrigendum to “New and Emerging Therapies for Osteoporosis”
por: Lewiecki, E. Michael, et al.
Publicado: (2017)

Anabolic Therapies
por: Lane, Nancy E., et al.
Publicado: (2010)

The Efficacy and Safety of Abaloparatide‐SC in Men With Osteoporosis: A Randomized Clinical Trial
por: Czerwinski, Edward, et al.
Publicado: (2022)

Anabolic androgenic steroids and cardiomyopathy: an update
por: Fadah, Kahtan, et al.
Publicado: (2023)

The Evidence for Efficacy of Osteoporosis Treatment in Men with Primary Osteoporosis: A Systematic Review and Meta-Analysis of Antiresorptive and Anabolic Treatment in Men
por: Schwarz, Peter, et al.
Publicado: (2011)

Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis: A meta-analysis
por: Lou, Shenghan, et al.
Publicado: (2017)

Newer anabolic therapies in osteopororsis
por: Mittal, Monika, et al.
Publicado: (2012)

Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2011)

Romosozumab: a novel bone anabolic treatment option for osteoporosis?
por: Kerschan-Schindl, Katharina
Publicado: (2019)

Long-term consequences of osteoporosis therapy with denosumab
por: Bandeira, Francisco, et al.
Publicado: (2022)

Anabolic therapy with Equisetum arvense along with bone mineralising nutrients in ovariectomized rat model of osteoporosis
por: Kotwal, Swati D., et al.
Publicado: (2016)

Rational polyelectrolyte nanoparticles endow preosteoclast-targeted siRNA transfection for anabolic therapy of osteoporosis
por: Zhang, Zheng, et al.
Publicado: (2023)

Analysis of Serum Proteome after Treatment of Osteoporosis with Anabolic or Antiresorptive Drugs
por: del Real, Alvaro, et al.
Publicado: (2022)

Therapeutic Anabolic and Anticatabolic Benefits of Natural Chinese Medicines for the Treatment of Osteoporosis
por: He, Jianbo, et al.
Publicado: (2019)

Diagnosis and therapy of osteoporosis in geriatric trauma patients: an update
por: Schray, Deborah, et al.
Publicado: (2016)

Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis
por: Pietrogrande, Luca
Publicado: (2010)

Anabolic androgenic steroid-induced liver injury: An update
por: Petrovic, Ana, et al.
Publicado: (2022)

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
por: Bobba, Raja, et al.
Publicado: (2007)

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
por: Dal Molin, Graziela Z., et al.
Publicado: (2018)

Glucocorticoid-induced osteoporosis: an update
por: Compston, Juliet
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1ojguhbvvpfp7seas0avpdb5oi